Table 1.

Chronic myeloid leukemia example: how much better can a constrained optimal control regimen be, in comparison to various standard constant-dose regimens? The drugs represented by u₁ and u₂ are both targeted BCR-ABL1 inhibitors; the drug u₃ represents an immunotherapy adapted from [23]

Regimens (doses in mg)			Value after 5 years
u 1	u 2	u 3	Objective functional
400	0	0	280 × 103
0	140	0	212 × 103
0	0	240	471 × 103
0	70	80	233 × 103
200	70	0	40.7 × 103
200	70	80	37.9 × 103
Constrained approx. to optimal regimen			28.7 × 103